Clinical biomarkers in multiple sclerosis

Bibliography

• Martin R, Bielekova B, Hohlfeld R, Biomarkers in multiple sclerosis. Dis Markers 2006;22(4):183-5
   PubMed Web of Science ®Google Scholar
• Harris VK, Sadiq SA. Disease biomarkers in multiple sclerosis: potential for use in therapeutic decision making. Mol Diagn Ther 2009;13:225-44
   PubMed Web of Science ®Google Scholar
• Bielekova B, Martin R. Development of biomarkers in multiple sclerosis. Brain 2004;127(Pt 7):1463-78
   PubMedGoogle Scholar
• Vercellino M, Romagnolo A, Mattioda A, Multiple sclerosis relapses: a multivariable analysis of residual disability determinants. Acta Neurol Scand 2009;119(2):126-30
   PubMed Web of Science ®Google Scholar
• Nilsagard Y, Lundholm C, Gunnarsson LG, Dcnison E. Clinical relevance using timed walk tests and ‘timed up and go’ testing in persons with multiple sclerosis. Physiother Res Int 2007;12(2):105-14
   PubMedGoogle Scholar
• Zackowski KM, Smith SA, Reich DS, Sensorimotor dysfunction in multiple sclerosis and column-specific magnetization transfer-imaging abnormalities in the spinal cord. Brain 2009;132(Pt 5):1200-9
   PubMedGoogle Scholar
• Cohen BA. Identification, causation, alleviation, and prevention of complications (ICAP): an approach to symptom and disability management in multiple sclerosis. Neurology 2008;71(24 Suppl 3):S14-20
   PubMed Web of Science ®Google Scholar
• Rudick RA, Miller D, Hass S, AFFIRM and SENTINEL Investigators. Health-related quality of life in multiple sclerosis: effects of natalizumab. Ann Neurol 2007;62(4):335-46
   PubMed Web of Science ®Google Scholar
• Amato MP, Zipoli V, Portaccio E. Cognitive changes in multiple sclerosis. Expert Rev Neurother 2008;8(10):1585-96
   PubMedGoogle Scholar
• Scherer P. Cognitive screening in multiple sclerosis. J Neurol 2007;254(Suppl 2):II26-9
   PubMedGoogle Scholar
• Hoffmann S, Tittgemeyer M, von Cramon DY. Cognitive impairment in multiple sclerosis. Curr Opin Neurol 2007;20(3):275-80
   PubMed Web of Science ®Google Scholar
• Rogers JM, Panegyres PK. Cognitive impairment in multiple sclerosis: evidence-based analysis and recommendations. J Clin Neurosci 2007;14(10):919-27
   PubMed Web of Science ®Google Scholar
• Lynch SG, Dickerson KJ, Denney DR. Evaluating processing speed in multiple sclerosis: a comparison of two rapid serial processing measures. Clin Neuropsychol 2010;24:963-76
   PubMed Web of Science ®Google Scholar
• Frohman E, Costello F, Zivadinov R, Optical coherence tomography in multiple sclerosis. Lancet Neurol 2006;5(10):853-63
   PubMed Web of Science ®Google Scholar
• Pulicken M, Gordon-Lipkin E, Balcer LJ, Optical coherence tomography and disease subtype in multiple sclerosis. Neurology 2007;69(22):2085-92
   PubMed Web of Science ®Google Scholar
• Mowry EM, Loguidice MJ, Daniels AB, Vision-related quality of life in multiple sclerosis: correlation with new measures of low- and high-contrast letter acuity. J Neurol Neurosurg Psychiatry 2009;80(7):767-72
   PubMed Web of Science ®Google Scholar
• Watanabe A, Matsushita T, Doi H, Multimodality-evoked potential study of anti-aquaporin-4 antibody-positive and -negative multiple sclerosis patients. J Neurol Sci 2009;281(1-2):34-40
   PubMed Web of Science ®Google Scholar
• Kolappan M, Henderson AP, Jenkins TM, Assessing structure and function of the afferent visual pathway in multiple sclerosis and associated optic neuritis. J Neurol 2009;256(3):305-19
   PubMed Web of Science ®Google Scholar
• Khanifar AA, Parlitsis GJ, Ehrlich JR, Retinal nerve fiber layer evaluation in multiple sclerosis with spectral domain optical coherence tomography. Clin Ophthalmol 2010;4:1007-13
   PubMedGoogle Scholar
• Tsoi VL, Hill KE, Carlson NG, Immunohistochemical evidence of inducible nitric oxide synthase and nitrotyrosine in a case of clinically isolated optic neuritis. J Neuroophthalmol 2006;26(2):87-9
   PubMed Web of Science ®Google Scholar
• Klistorner A, Arvind H, Nguyen T, Axonal loss and myelin in early ON loss in postacute optic neuritis. Ann Neurol 2008;64(3):325-31
   PubMed Web of Science ®Google Scholar
• Meuth SG, Bittner S, Seiler C, Natalizumab restores evoked potential abnormalities in patients with relapsing-remitting multiple sclerosis. Mult Scler 2011;17:198-203
   Google Scholar
• Barcellos LF, Sawcer S, Ramsay PP, Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis. Hum Mol Genet 2006;15(18):2813-24
   PubMed Web of Science ®Google Scholar
• Zivadinov R, Uxa L, Bratina A, HLA-DRB1*1501, -DQB1*0301, -DQB1*0302, -DQB1*0602, and -DQB1*0603 alleles are associated with more severe disease outcome on MRI in patients with multiple sclerosis. Int Rev Neurobiol 2007;79:521-35
   PubMed Web of Science ®Google Scholar
• Lincoln MR, Ramagopalan SV, Chao MJ, Epistasis among HLA-DRB1, HLA-DQA1, and HLA-DQB1 loci determines multiple sclerosis susceptibility. Proc Natl Acad Sci USA 2009;106(18):7542-7
   PubMed Web of Science ®Google Scholar
• Matsuoka T, Matsushita T, Osoegawa M, Association of the HLA-DRB1 alleles with characteristic MRI features of Asian multiple sclerosis. J Mult Scler 2008;14(9):1181-90
   PubMed Web of Science ®Google Scholar
• Okuda DT, Srinivasan R, Oksenberg JR, Genotype-phenotype correlations in multiple sclerosis: HLA genes influence disease severity inferred by 1HMR spectroscopy and MRI measures. Brain 2009;132(Pt 1):250-9
   PubMedGoogle Scholar
• De Jager PL, Simon KC, Munger KL, Integrating risk factors: HLA-DRB1*1501 and Epstein-Barr virus in multiple sclerosis. Neurology 2008;70(13 Pt 2):1113-18
   PubMed Web of Science ®Google Scholar
• Weber F, Fontaine B, Cournu-Rebeix I, IL2RA and IL7RA genes confer susceptibility for multiple sclerosis in two independent European populations. Genes Immun 2008;9(3):259-63
   PubMed Web of Science ®Google Scholar
• Gregory SG, Schmidt S, Seth P, ; Multiple Sclerosis Genetics Group. Interleukin 7 receptor alpha chain (IL7R) shows allelic and functional association with multiple sclerosis. Nat Genet 2007;39(9):1083-91
   PubMed Web of Science ®Google Scholar
• Hafler DA, Compston A, Sawcer S, International Multiple Sclerosis Genetics Consortium Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med 2007;357(9):851-62
   PubMed Web of Science ®Google Scholar
• Baranzini SE, Wang J, Gibson RA, Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. Hum Mol Genet 2009;18(4):767-78
   PubMed Web of Science ®Google Scholar
• Ban M, Goris A, Lorntzen AR, Replication analysis identifies TYK2 as a multiple sclerosis susceptibility factor. Eur J Hum Genet 2009;17:1309-13
   PubMed Web of Science ®Google Scholar
• Bieber AJ, Suwansrinon K, Kerkvliet J, Allelic variation in the Tyk2 and EGF genes as potential genetic determinants of CNS repair. Proc Natl Acad Sci USA 2010;107:792-7
   PubMed Web of Science ®Google Scholar
• Zuvich RL, McCauley JL, Oksenberg JR, International Multiple Sclerosis Genetics Consortium, Genetic variation in the IL7RA/IL7 pathway increases multiple sclerosis susceptibility. Hum Genet 2010;127(5):525-35
   PubMedGoogle Scholar
• Illes Z, Safrany E, Peterfalvi A, 3′UTR C2370A allele of the IL-23 receptor gene is associated with relapsing-remitting multiple sclerosis. Neurosci Lett 2008;431(1):36-8
   PubMed Web of Science ®Google Scholar
• Roos IM, Kockum I, Hillert J. The interleukin 23 receptor gene in multiple sclerosis: a case-control study. J Neuroimmunol 2008;194(1-2):173-80
   PubMed Web of Science ®Google Scholar
• Satoh J, Misawa T, Tabunoki H, Molecular network analsis of T-cell transcriptome suggest abberrant regulation of gene expression by NF-KappaB as a biomarker for relapse of multiple sclerosis. Dis Markers 2008;25(1):27-35
   PubMed Web of Science ®Google Scholar
• Corvol JC, Pelletier D, Henry RG, Abrogation of T cell quiescence characterizes patients at high risk for multiple sclerosis after the initial neurological event. Proc Natl Acad Sci USA 2008;105(33):11839-44
   PubMed Web of Science ®Google Scholar
• Maier LM, Lowe CE, Cooper J, IL2RA genetic heterogeneity in multiple sclerosis and type 1 diabetes susceptibility and soluble interleukin-2 receptor production. PLoS Genet 2009;5(1):e1000322
   PubMedGoogle Scholar
• Ban M, Booth DR, Heard RN, Internatinal Multiple Sclerosis Genetics Consortium. The expanding genetic overlap between multiple sclerosis and type 1 diabetes. Genes Immun 2009;10:11-14
   PubMed Web of Science ®Google Scholar
• Alcina A, Fedetz M, Ndagire D, IL2RA/CD25 gene polymorphisms: uneven association with multiple sclerosis (MS) and type 1 diabetes (T1D). PLoS ONE 2009;4(1):e4137
   PubMedGoogle Scholar
• Hauser SL, Johnston SC. Personalized genetic scans: with gifts like these. Ann Neurol 2009;65(3):A7-9
   PubMed Web of Science ®Google Scholar
• O'Connor KC, Roy SM, Becker CH, Comprehensive phenotyping in multiple sclerosis: discovery based proteomics and the current understanding of putative biomarkers. Dis Markers 2006;22(4):213-25
   PubMed Web of Science ®Google Scholar
• Scarisbrick IA, Linbo R, Vandell AG, Kallikreins are associated with secondary progressive multiple sclerosis and promote neurodegeneration. Biol Chem 2008;389(6):739-45
   PubMed Web of Science ®Google Scholar
• Tenorio-Laranga J, Coret-Ferrer F, Casanova-Estruch B, Prolyl oligopeptidase is inhibited in relapsing-remitting multiple sclerosis. J Neuroinflammation 2010;7:23
   PubMed Web of Science ®Google Scholar
• Fox RJ, Kivisakk P, Lee JC, Chemokine receptors as biomarkers in multiple sclerosis. Dis Markers 2006;22(4):227-33
   PubMed Web of Science ®Google Scholar
• Lopez C, Comabella M, Tintore M, Variations in chemokine receptor and cytokine expression during pregnancy in multiple sclerosis patients. Mult Scler 2006;12(4):421-7
   PubMed Web of Science ®Google Scholar
• Maier LM, Anderson DE, Severson CA, Soluble IL-2RA levels in multiple sclerosis subjects and the effect of soluble IL-2RA on immune responses. J Immunol 2009;182(3):1541-7
   PubMed Web of Science ®Google Scholar
• Sternberg Z, Weinstock-Guttman B, Hojnacki D, Soluble receptor for advanced glycation end products in multiple sclerosis: a potential marker of disease severity. Mult Scler 2008;14(6):759-63
   PubMed Web of Science ®Google Scholar
• Jurewicz A, Matysiak M, Raine CS, Selmaj K. Soluble Nogo-A, an inhibitor of axonal regeneration, as a biomarker for multiple sclerosis. Neurology 2007;68(4):283-7
   PubMed Web of Science ®Google Scholar
• Selmaj K, Jurewicz A, Matysiak M, Raine CS. Soluble Nogo-A in CSF is not a useful biomarker for multiple sclerosis. Neurology 2009;72(19):1708-9
   PubMed Web of Science ®Google Scholar
• Hayes C, Cabtira N, DeLuca H. Vitamin D and multiple sclerosis. Proc Soc Exo Buik Med 1997;216:21-7
   PubMed Web of Science ®Google Scholar
• Ascherio A, Munger K. Environmental riskfactors in multiple sclerosis. Part II: noninfectious factors. Ann Neurol 2007;61:504-13
   PubMed Web of Science ®Google Scholar
• Holick MF. High prevalence of vitamin D inadequacy and implications for health. Mayo Clin Proc 2006;81(3):353-73
   PubMed Web of Science ®Google Scholar
• Ramagopalan SV, Maugeri NJ, Handunnetthi L, Expression of the multiple sclerosis-associated MHC class II Allele HLA-DRB1*1501 is regulated by vitamin D. PLoS Genet 2009;5(2):e1000369
   PubMedGoogle Scholar
• Mowry EM, Krupp LB, Milazzo M, Vitamin D status is associated with relapse rate in pediatric-onset multiple sclerosis. Ann Neurol 2010;67(5):618-24
   PubMed Web of Science ®Google Scholar
• Simpson S Jr, Taylor B, Blizzard L, Higher 25-hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis. Ann Neurol 2010;68(2):193-203
   PubMed Web of Science ®Google Scholar
• Smolders J, Menheere P, Kessels A, Association of vitamin D metabolite levels with relapse rate and disability in multiple sclerosis. Mult Scler 2008;14:1220-24
   PubMed Web of Science ®Google Scholar
• Handunnetthi L, Ramagopalan SV, Evers GC. Multiple sclerosis, vitamin D, and HLA-DRB1*15. Neurology 2010;74:1905-10
   PubMed Web of Science ®Google Scholar
• Burton JM, Kimball S, Vieth R, A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. Neurology 2010;74:1852-59
   PubMed Web of Science ®Google Scholar
• Wingerchuk DM. Supplementing our understanding of vitamin D and multiple sclerosis. Neurology 2010;74:1846-47
   PubMed Web of Science ®Google Scholar
• van der Voort LF, Vennegoor A, Visser A, Spontaneous MxA mRNA level predicts relapses in patients with recently diagnosed MS. Neurology 2010;75(14):1228-33
   PubMed Web of Science ®Google Scholar
• Reder AT. MxA: a biomarker for predicting multiple sclerosis disease activity. Neurology 2010;75(14):1222-3
   PubMed Web of Science ®Google Scholar
• Hesse D, Soelberg SF, Sorensen P. Absence of MxA induction by interferon Beta in patients with MS reflects complete loss of bioactivity. Neurology 2009;73:372-77
   PubMed Web of Science ®Google Scholar
• Sawai S, Umemura H, Mori M, Serum levels of complement C4 fragments correlate with disease activity in multiple sclerosis: proteomic analysis. J Neuroimmunol 2010;218(1-2):112-15
   PubMed Web of Science ®Google Scholar
• Ingram G, Hakobyan S, Robertson NP, Morgan BP. Elevated plasma C4a levels in multiple sclerosis correlate with disease activity. J Neuroimmunol 2010;223(1-2):124-7
   PubMed Web of Science ®Google Scholar
• Ingram G, Hakobyan S, Hirst CL, Complement regulator factor H as a serum biomarker of multiple sclerosis disease state. Brain 2010;133(Pt 6):1602-11
   PubMedGoogle Scholar
• Symaya CV, Meyers LW, Elison GW, Ench Y. Increased prevalence and titer of Epstein Barr virus antibodies in patients with multiple sclerosis. Ann Neurol 1985;17:371-7
   PubMed Web of Science ®Google Scholar
• Ramagopalan SV, Valdar W, Dyment DA, ; Canadian Collaborative Study Group. Association of infectious mononucleosis with multiple sclerosis. a population-based study. Neuroepidemiology 2009;32(4):257-62
   PubMed Web of Science ®Google Scholar
• Lunemann JD, Tintore M, Messmer B, Elevated Epstein-Barr virus-encoded nuclear antigen-1 immune responses predict conversion to multiple sclerosis. Ann Neurol 2010;67:159-69
   PubMed Web of Science ®Google Scholar
• Farrell RA, Antony D, Wall GR, Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI. Neurolgy 2009;73:32-8
   PubMed Web of Science ®Google Scholar
• Ingram G, Bugert JJ, Loveless S, Robertson NP. Anti-EBNA-1 IgG is not a reliable marker of multiple sclerosis clinical disease activity. Eur J Neurol 2010;17:1386-89
   PubMed Web of Science ®Google Scholar
• Ascherio A, Bar-Or A. EBV and brain matter(s)? Neurology 2010;74:1092-95
   PubMed Web of Science ®Google Scholar
• Swanborg RH, Whittum-Hudson JA, Hudson AP. Infectious agents and multiple sclerosis–are Chlamydia pneumonia and human herpes virus 6 involved? J Neuroimmunol 2003;136(1-2):1-8
   PubMed Web of Science ®Google Scholar
• Berger T, Reindl M. Biomarkers in multiple sclerosis: role of antibodies. Dis Markers 2006;22(4):207-12
   PubMed Web of Science ®Google Scholar
• Kuhle J, Lindberg RL, Regeniter A, Antimyelin antibodies in clinically isolated syndromes correlate with inflammation in MRI and CSF. J Neurol 2007;254(2):160-8
   PubMed Web of Science ®Google Scholar
• Belogurov AA Jr, Kurkova IN, Friboulet A, Recognition and degradation of myelin basic protein peptides by serum autoantibodies: novel biomarker for multiple sclerosis. J Immunol 2008;180(2):1258-67
   PubMed Web of Science ®Google Scholar
• Dotan N, Altstock RT, Schwarz M, Dukler A. Anti-glycan antibodies as biomarkers for diagnosis and prognosis. Lupus 2006;15(7):442-50
   PubMed Web of Science ®Google Scholar
• Freedman M, Laks J, Dotan N, Anti-{alpha}-glucose-based glycan IgM antibodies predict relapse activity in multiple sclerosis after the first neurological event. Mult Scler 2009;15:422-30
   PubMed Web of Science ®Google Scholar
• Brettschneider J, Jaskowski TD, Tumani H, Serum anti-GAGA4 IgM antibodies differentiate relapsing remitting and secondary progressive multiple sclerosis from primary progressive multiple sclerosis and other neurological diseases. J Neuroimmunol 2009;217(1-2):95-101
   PubMed Web of Science ®Google Scholar
• Munteis E, Cano JF, Flores JA, Prevalence of autoimmune thyroid disorders in a Spanish multiple sclerosis cohort. Eur J Neurol 2007;14(9):1048-52
   PubMed Web of Science ®Google Scholar
• Weinshenker BG, Wingerchuk DM, Pittock SJ, NMO-IgG: a specific biomarker for neuromyelitis optica. Dis Markers 2006;22(4):197-206
   PubMed Web of Science ®Google Scholar
• Weinshenker BG, Wingerchuk DM. Neuromyelitis optica: clinical syndrome and the NMO-IgG autoantibody marker. Curr Top Microbiol Immunol 2008;318:343-56
   PubMed Web of Science ®Google Scholar
• Miyazaki Y, Iwabuchi K, Kikuchi S, Expansion of CD4+CD28- T cells producing high levels of interferon-{gamma} in peripheral blood of patients with multiple sclerosis. Mult Scler 2008;14(8):1044-55
   PubMed Web of Science ®Google Scholar
• Saresella M, Marventano I, Longhi R, CD4+CD25+FoxP3+PD1- regulatory T cells in acute and stable relapsing-remitting multiple sclerosis and their modulation by therapy. FASEB J 2008;22(10):3500-8
   PubMed Web of Science ®Google Scholar
• McKay FC, Swain LI, Schibeci SD, CD127 immunophenotyping suggests altered CD4+ T cell regulation in primary progressive multiple sclerosis. J Autoimmun 2008;31(1):52-8
   PubMed Web of Science ®Google Scholar
• Racke MK. The role of B cells in multiple sclerosis: rationale for B-cell-targeted therapies. Curr Opin Neurol 2008;21(Suppl 1):S9-18
   PubMedGoogle Scholar
• Bielekova B, Catalfamo M, Reichert-Scrivner S, Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci USA 2006;103(15):5941-6
   PubMed Web of Science ®Google Scholar
• Martinez-Rodriguez JE, Saez-Borderias A, Munteis E, Natural killer receptors distribution in multiple sclerosis: relation to clinical course and interferon-beta therapy. Clin Immunol 2010;137(1):41-50
   PubMed Web of Science ®Google Scholar
• van den Heuvel M, Peralta C, Bashar S, Trafficking of peripheral blood CD56(bright) cells to the decidualizing uterus–new tricks for old dogmas? J Reprod Immunol 2005;67(1-2):21-34
   PubMed Web of Science ®Google Scholar
• Sheremata WA, Jy W, Horstman LL, Evidence of platelet activation in multiple sclerosis. J Neuroinflammation 2008;5:27
   PubMed Web of Science ®Google Scholar
• Giovannoni G. Multiple sclerosis cerebrospinal fluid biomarkers. Dis Markers 2006;22(4):187-96
   PubMed Web of Science ®Google Scholar
• Link H, Huang YM. Oligoclonal bands in multiple sclerosis cerebrospinal fluid: an update on methodology and clinical usefulness. J Neuroimmunol 2006;180(1-2):17-28
   PubMed Web of Science ®Google Scholar
• Mares J, Herzig R, Urbanek K, Correlation of the IgG index and oligoclonal bands in the serebrospinal fluid of patients with multiple sclerosis. Biomed Papers 2008;152:247-9
   PubMed Web of Science ®Google Scholar
• Presslauer S, Milosavljevic D, Brucke T, Elevated levels of kappa free light chains in CSF support the diagnosis of multiple sclerosis. J Neurol 2008;255(10):1508-14
   PubMed Web of Science ®Google Scholar
• Koch M, Heersema D, Mostert J, Cerebrospinal fluid oligoclonal bands and progression of disability in multiple sclerosis. Eur J Neurol 2007;14(7):797-800
   PubMed Web of Science ®Google Scholar
• Rinker JR II, Trinkaus K, Naismith RT, Cross AH. Higher IgG index found in African Americans versus Caucasians with multiple sclerosis. Neurology 2007;69(1):68-72
   PubMed Web of Science ®Google Scholar
• Joseph FG, Hirst CL, Pickersgill TP. CSF oligoclonal band status informs prognosis in multiple sclerosis: a case control study of 100 patients. J Neurol Neurosurg Psychiatry 2009;80(3):292-6
   PubMed Web of Science ®Google Scholar
• Mandrioli J, Sola P, Bedin R, A multifactorial prognostic index in multiple sclerosis. Cerebrospinal fluid IgM oligoclonal bands and clinical features to predict the evolution of the disease. Eur J Neurol 2008;255(7):1023-31
   Google Scholar
• Villar L, Garcia-Barragan N, Espino M, Influence of oligoclonal IgM specificity in multiple sclerosis disease course. Mult Scler 2008;14(2):183-7
   PubMed Web of Science ®Google Scholar
• Vogt M, Teunissen CE, Iacobaeus E, CSF anti-myelin antibodies are related to MR measures of disease activity in multiple sclerosis. J Neurol Neurosurg Psychiatry 2009;80(10):1110-15
   PubMed Web of Science ®Google Scholar
• Thangarajh M, Gomez-Rial J, Hedstrom A, Lipid specific immunoglobulin M in CSF predicts adverse long-term outcome in multiple sclerosis. Mult Scler 2008;14:1208-13
   PubMed Web of Science ®Google Scholar
• Svarcova J, Fialova L, Bartos A, Cerebrospinal fluid antibodies to tubulin are elevated in the patients with multiple sclerosis. Eur J Neurol 2008;15:1173-9
   PubMed Web of Science ®Google Scholar
• Bartos A, Fialova L, Soukpova J, Elevated intrathecal antibodies against the medium neurofilament subunit in multiple sclerosis. J Neurol 2007;254:20-5
   PubMed Web of Science ®Google Scholar
• Bartos A, Fialova L, Soukpova J, Antibodies against light neurofilaments in multiple sclerosis. Acta Neurol Scand 2007;116:100-7
   PubMed Web of Science ®Google Scholar
• Giovannoni G. Cerebrospinal fluid neurofilament: the biomarker that will resuscitate the ‘Spinal Tap’. Mult Scler 2010;16:285-6
   PubMed Web of Science ®Google Scholar
• Salzer J, Svenningsson A, Sundstrom P. Neurofilament light as a prognostic marker in multiple sclerosis. Mult Scler 2010;16:287-92
   PubMed Web of Science ®Google Scholar
• Bornsen L, Khademi M, Olsson T, Ossteopontin concentrations are increased in cerebrospinal fluid during attacks of multiple sclerosis. Mult Scler 2011;17:32-42
   Google Scholar
• Malmestrom C, Lycke J, Haghighi S, Relapses in multiple sclerosis are associated with increased CD8+ cytoxicity in CSF. J Neuroimmunol 2008;196:159-65
   PubMed Web of Science ®Google Scholar
• Braitch M, Nunan R, Niepel G, Increased osteopontin levels in the cerebrospinal fluid of patient with multiple sclerosis. Arch Neurol 2008;65:633-5
   PubMed Web of Science ®Google Scholar
• Chowdhury S, Lin J, Sadiq S. Specificity and correlation with disease activity of cerebrospinal fluid osteopontin levels in patients with the multiple sclerosis. Arch Neurol 2008;65:232-5
   PubMed Web of Science ®Google Scholar
• Jurewucz A, Matysiak M, Raine C, Selmaj K. Soluble Nogo-A, an inhibitor of axonal regeneration as a biomarker for multiple sclerosis. Neurology 2007;68:283-7
   PubMed Web of Science ®Google Scholar
• Lindsey J, Crawford M, Hatfield L. Soluble Nogo-A is not a useful biomarker for multiple sclerosis. Neurology 2008;71:35-7
   PubMed Web of Science ®Google Scholar
• Fainardi E, Rizzo R, Merchiorri L, CSF levels of soluble HLA-G and Fas molecules are inversely associated to MRI evidence of disease activity in patients with relapsing and remitting multiple sclerosis. Mult Scler 2008;14:446-54
   PubMed Web of Science ®Google Scholar
• Khademi M, Bornsen L, Rafatnia F, The effects of natalizumab on inflammatory mediators in multiple sclerosis: prospects for treatment-sensitive biomarkers. Eur J Neurol 2009;16(4):528-36
   PubMed Web of Science ®Google Scholar
• Tumani H, Teunissen C, Sussmuth S, Cerebrospinal fluid biomarkers of neurodegeneration in chronic neurological diseases. J Expert Rev Mol Diagn 2008;8(4):479-94
   PubMed Web of Science ®Google Scholar
• Chiasserini D, Di Filippo M, Candeliere A, CSF proteome analysis in multiple sclerosis patients by two-dimensional electrophoresis. Eur J Neurol 2008;15(9):998-1001
   PubMed Web of Science ®Google Scholar
• Qin Z, Qin Y, Liu S. Alteration of DBP levels in CSF of patients with MS by proteomics analysis. Cell Mol Neurobiol 2009;29(2):203-10
   PubMed Web of Science ®Google Scholar
• Stoop MP, Dekker LJ, Titulaer MK, Quantitative matrix-assisted laser desorption ionization-Fourier transform ion cyclotron resonance (MALDI-FT-ICR) peptide profiling and identification of multiple-sclerosis-related proteins. J Proteome Res 2009;8(3):1404-14
   PubMed Web of Science ®Google Scholar
• Harris VK, Diamanduros A, Good P, Bri2-23 is a potential cerebrospinal fluid biomarker in multiple sclerosis. Neurobiol Dis 2010;40(1):331-9
   PubMed Web of Science ®Google Scholar
• Comabella M, Fernandez M, Martin R, Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis. Brain 2010;133(Pt 4):1082-93
   PubMedGoogle Scholar
• Brettschneider J, Czerwoniak A, Senel M, The chemokine CXCL13 is a prognostic marker in clinically isolated syndrome (CIS). PLoS One 2010;5(8):e11986
   PubMedGoogle Scholar
• Brynedal B, Khademi M, Wallstrom E, Gene expression profiling in multiple sclerosis: a disease of the central nervous system, but with relapses triggered in the periphery? Neurobiol Dis 2010;37(3):613-21
   PubMed Web of Science ®Google Scholar
• Winges KM, Gilden DH, Bennett JL, Analysis of multiple sclerosis cerebrospinal fluid reveals a continuum of clonally related antibody-secreting cells that are predominantly plasma blasts. J Neuroimmunol 2007;192(1-2):226-34
   PubMed Web of Science ®Google Scholar
• Owens GP, Winges KM, Ritchie AM, VH4 gene segments dominate the intrathecal humoral immune response in multiple sclerosis. J Immunol 2007;179(9):6343-51
   PubMed Web of Science ®Google Scholar
• Obermeier B, Mentele R, Malotka J, Matching of oligoclonal immunoglobulin transcriptomes and proteomes of cerebrospinal fluid in multiple sclerosis. Nat Med 2008;14(6):688-93
   PubMed Web of Science ®Google Scholar
• Kuenz B, Lutterotti A, Ehling R, Cerebrospinal fluid B cells correlate with early brain inflammation in multiple sclerosis. PLoS ONE 2008;3(7):e2559
   PubMedGoogle Scholar
• Petkau J, Reingold SC, Held U, Magnetic resonance imaging as a surrogate outcome for multiple sclerosis relapses. Mult Scler 2008;14(6):770-8
   PubMed Web of Science ®Google Scholar
• Mattson DH. Update on the diagnosis of multiple sclerosis. Expert Rev Neurother 2002;2(3):319-28
   PubMedGoogle Scholar
• Sormani MP, Bonzano L, Roccatagliata L, Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approach. Ann Neurol 2009;65(3):268-75
   PubMed Web of Science ®Google Scholar
• Agosta F, Absinta M, Sormani MP, In vivo assessment of cervical cord damage in MS patients: a longitudinal diffusion tensor MRI study. Brain 2007;130(Pt 8):2211-19
   PubMedGoogle Scholar
• Bielekova B, Kadom N, Fisher E, MRI as a marker for disease heterogeneity in multiple sclerosis. Neurology 2005;65(7):1071-6
   PubMed Web of Science ®Google Scholar
• Fisniku LK, Chard DT, Jackson JS, Gray matter atrophy is related to long-term disability in multiple sclerosis. Ann Neurol 2008;64(3):247-54. Erratum in: Ann Neurol. 2009;65(2):232
   PubMed Web of Science ®Google Scholar
• van Veen T, Nielsen J, Berkhof J, CCL5 and CCR5 genotypes modify clinical, radiological and pathological features of multiple sclerosis. J Neuroimmunol 2007;190(1-2):157-64
   PubMed Web of Science ®Google Scholar
• Fox RJ, Kivisakk P, Fisher E, Multiple sclerosis: chemokine receptor expression on circulating lymphocytes in correlation with radiographic measures of tissue injury. Mult Scler 2008;14(8):1036-43
   PubMed Web of Science ®Google Scholar
• Moll NM, Cossoy MB, Fisher E, Imaging correlates of leukocyte accumulation and CXCR4/CXCL12 in multiple sclerosis. Arch Neurol 2009;66(1):44-53
   PubMed Web of Science ®Google Scholar
• Mostert JP, Blaauw Y, Koch MW, Reproducibility over a 1-month period of 1H-MR spectroscopic imaging NAA/Cr ratios in clinically stable multiple sclerosis patients. Eur Radiol 2008;18(8):1736-40
   PubMed Web of Science ®Google Scholar
• Rigotti DJ, Inglese M, Gonen O. Whole-brain N-acetylaspartate as a surrogate marker of neuronal damage in diffuse neurologic disorders. AJNR Am J Neuroradiol 2007;28(10):1843-9
   PubMed Web of Science ®Google Scholar
• Henry RG, Shieh M, Okuda DT, Regional grey matter atrophy in clinically isolated syndromes at presentation. J Neurol Neurosurg Psychiatry 2008;79(11):1236-44
   PubMed Web of Science ®Google Scholar
• Naismith RT, Xu J, Tltlam NT, Radial diffusivity in remote optic neuritis discriminates visual outcomes. Neurology 2010;74(21):1702-10
   PubMed Web of Science ®Google Scholar
• Mittal S, Wu Z, Neelavalli J, Haacke EM. Susceptibility-weighted imaging: technical aspects and clinical applications, part 2. AJNR Am J Neuroradiol 2009;30:232-52
   PubMed Web of Science ®Google Scholar
• Kolbe S, Chapman C, Nguyen T, Optic nerve diffusion changes and atrophy jointly predict visual dysfunction after optic neuritis. Neuroimage 2009;15:679-86
   Google Scholar
• Kolappan M, Henderson AP, Jenkins TM, Assessing structure and function of the afferent visual pathway in multiple sclerosis and associated optic neuritis. J Neurol 2009;256(3):305-19
   PubMed Web of Science ®Google Scholar
• Simon B, Schmidt S, Lukas C, Improved in vivo detection of cortical lesions in multiple sclerosis using double inversion recovery MR imaging at 3 Tesla. Eur Radiol 2010;20(7):1675-83
   PubMed Web of Science ®Google Scholar
• Polman CH, Bertolotto A, Deisenhammer F, Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. Lancet Neurol 2010;9(7):740-50
   PubMed Web of Science ®Google Scholar
• Wiesemann E, Deb M, Hemmer B, Early identification of interferon-beta responders by ex vivo testing in patients with multiple sclerosis. Clin Immunol 2008;128(3):306-13
   PubMed Web of Science ®Google Scholar
• Krakauer M, Sorensen P, Khademi M, Increased IL-10 mRNA and IL-23 mRNA expression in multiple sclerosis: interferon-beta treatment increases IL-10 mRNA expression while reducing IL-23 mRNA expression. Mult Scler 2008;14(5):622-30
   PubMed Web of Science ®Google Scholar
• Malucchi S, Gilli F, Caldano M, Predictive markers for response to interferon therapy in patients with multiple sclerosis. Neurology 2008;70(13 Pt 2):1119-27
   PubMed Web of Science ®Google Scholar
• Saraste M, Irjala H, Airas L. Expansion of CD56Bright natural killer cells in the peripheral blood of multiple sclerosis patients treated with interferon-beta. Neurol Sci 2007;28(3):121-6
   PubMed Web of Science ®Google Scholar
• Jones JL, Phuah CL, Cox AL, IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). J Clin Invest 2009;119:2052-61
   PubMed Web of Science ®Google Scholar
• Martinez-foero I, Pelaez A, Villoslada P. Pharmcogenomics of multiple sclerosis: in search for a personalized therapy. Expert Opin Pharmacother 2008;9(17):3053-67
   PubMed Web of Science ®Google Scholar
• Vandenbroeck K, Matut C. Pharmacogenomics of the response to IFN-beta in multiple sclerosis: ramifications from the first genome-wide screen. Pharmocogenomics 2008;9(5):639-45
   PubMed Web of Science ®Google Scholar
• van der Voort LF, Kok A, Visser A, Interferon-beta bioactivity measurement in multiple sclerosis: feasibility for routine clinical practice. Mult Scler 2009;15:212-8
   PubMed Web of Science ®Google Scholar
• Byun E, Caillier SJ, Montalbam X, Genome wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis. Arch Neurol 2008;65(3):337-44
   PubMed Web of Science ®Google Scholar
• Wekerle H, Hohfeld R. Molecular oracles for multiple sclerosis therapy. Nat Med 2010;16(4):376-7
   PubMed Web of Science ®Google Scholar
• Axtell RC, de Jong BA, Boniface K, T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis. Nat Med 2010;16(4):406-12
   PubMed Web of Science ®Google Scholar
• Abstracts: 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). 15th Annual Conference of Rehabilitation in MS (RIMS). Mult Scler 2010;16:S7-352
   Google Scholar